News
Zacks.com on MSN17h
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
Madrigal Pharmaceuticals ( NASDAQ: MDGL) has received conditional marketing approval from the European Commission for ...
Conshohocken, Pennsylvania Thursday, August 21, 2025, 14:00 Hrs [IST] ...
Although there are other treatments in development, Wegovy could carve out a decent market for itself in MASH, especially ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback